T cell proliferative responses to synthetic peptides taken from the human nicotinic acetylcholine receptor (AChR) a-chain sequence, or to whole AChR purified from electric fish (Torpedo marmorata), have been studied, using blood, thymus, and lymph node cells, from 34 patients with myasthenia gravis (MG) and 17 controls mostly with other neurological diseases. Peptides were selected because they contained amino acid motifs that recur in most defined T cell epitopes. Peptide 257-269 (from the extracellular loop of the AChR a-chain between the second and third trans-membrane domains) stimulated cells from six patients and no controls. Peptides from region 125-143 (from the main extracellular 1-210 stretch), which is thought to be an important T cell epitope in rats, provoked responses in 26% of patients and 41% of controls. Two patients responded both to these peptides and to peptide 257-269, thereby implying some heterogeneity of their reacting T cells.
Introduction
Myasthenia gravis (MG)' is an autoimmune disease in which antibodies are produced that bind to acetylcholine receptors (AChR) in the postsynaptic membrane at the neuromuscular junction (1) . This leads to loss of receptors and muscle weak- 1 . Abbreviations used in this paper: AChR, acetylcholine receptor, LEMS, Lambert-Eaton myasthenic syndrome; MG, myasthenia gravis; MIR, main immunogenic region; SI, stimulation index; S-S, disulphide bond. ness. Production of anti-AChR antibodies by B cells is T celldependent in experimental animals (2) , and this is also likely to be the case in MG patients. Recently, AChR-specific T cell lines have been isolated from peripheral blood and thymus tissue of MG patients (3, 4) .
The AChRs found at the neuromuscular junction are pentameric structures comprising a2, $, Y, 6 subunits (1). Approximately 60% of anti-AChR antibodies found in MG sera are directed at conformational determinants on the two a-subunits known as the main immunogenic region (MIR) (5) that probably consists of several nonlinear sites on the extracellular surface. Recent evidence suggests that the majority of AChRspecific T cells also recognize epitopes on the a-subunit (6) . Inasmuch as T cells usually respond to sequential determinants rather than the native conformation of the stimulating antigen (7), short peptides may be sufficient provided that they contain the components necessary to bind to the T cell receptor and interact with self MHC molecules. It has been proposed by Rothbard and Taylor (8) that the majority of T cell epitopes contain within their structure a common motif of four or five amino acids in the following sequence: (1) charged or glycine, (2) hydrophobic, (3) hydrophobic, (4) charged, polar or hydrophobic. If the fourth residue is hydrophobic, the fifth must be charged or polar. The exact location of the T cell epitopes on the human AChR that initiate the pathogenic autoimmune reaction in MG is presently unknown. Their identification might provide clues about possible provoking agents in MG as well as about the repertoire of the T cell receptors that recognize them. The present study attempts to identify these sites on the a-subunit using synthetic human peptide sequences containing the common motifs described above.
Methods
Lymphocytes. Peripheral blood lymphocytes (PBL) were obtained from 34 MG patients (33 white, 1 black). 25 had disease onset before the age of 40 yr ("young onset"), 5 after 40 ("old onset"); a further 4 patients had a thymoma. Only two patients were receiving immunosuppressive diug treatment at the time of study. Controls comprised three cases of multiple sclerosis, one patient with cerebellar syndrome in association with ovarian cancer (a condition in which autoantibodies to cerebellar Purkinje cells are present in serum), five with paraproteinemic peripheral neuropathy, four with the Lambert-Eaton myasthenic syndrome (LEMS), and four healthy laboratory workers.
Lymphocytes were separated from heparinized blood by centrifugation on Ficoll-Hypaque, washed in HBSS (Gibco, Grand Island, NY) three times, and then resuspended in RPMI 1640 (Gibco) containing antibiotics and 10% human A' serum. Thymic lymphocytes were also obtained by mechanical disruption (9) from seven of the MG patients undergoing therapeutic thymectomy. In most cases, low-density fractions from discontinuous FicollHypaque gradients were used (10) . Mediastinal lymph nodes from three ofthese patients were teased apart and the cells were then washed and diluted in RPMI 1640 plus 10% human A' serum. Peptides. 11 different synthetic peptides representing sequences of the human a-subunit of the AChR, and one from the Torpedo marmorata sequence (representing the major site of a-bungarotoxin binding) were prepared on a peptide synthesizer (model 430A, Applied Biosystems Inc., Foster City, Ca.) using commercially available reagents as described (11) . The purity of each peptide was analyzed by amino acid analysis and analytical high performance liquid chromatography (HPLC) on a C-18 reverse-phase column and ranged from 72% to 96% purity. The sequences of these peptides are shown in Table  I . Peptides were dissolved in deionized water, sometimes requiring the addition ofacid or alkali to solubilize them completely, adjusted to pH 7.5, and stored at I mg/ml in aliquots at -70'C. Purified whole Torpedo AChR was prepared by affinity chromatography on cobratoxin columns and eluted with carbamylcholine as previously described (12 . -myasthen i a grav i s to peptides. These lines were maintained in culture by restimulation at 7-10-d intervals with the relevant antigen in the presence of autologous irradiated (1,500 rads) PBL as feeder cells, followed by further expansion in recombinant human interleukin 2 (IL-2) (Boehringer, Mannheim, Federal Republic ofGermany). From one ofthe cell lines, AChR-specific clones were obtained by limiting dilution and maintained in long-term culture by methods established for other T cell antigens (13) .
Proliferation assays. Fresh lymphocytes were cultured in triplicate in round-bottomed microtiter plates (Nunclon, Gibco) at 2 X 101 cells per well (5 X 101 per well for unseparated thymus cells), in 200 ul RPMI 1640 plus 10% human A' serum. The T cell lines were assayed for proliferation at 2.5 X I04 cells per well in the presence of 1 X 105 irradiated (1,500 rads) autologous feeder cells. Peptides were used at dilutions ranging from 50 to 0.001 ug/ml final concentrations in the assays. Most of the patients' lymphocytes were screened against the peptides at concentrations of 50 and 20 Ag/ml. Each assay plate also included triplicate wells containing 10 ug/ml Torpedo AChR, PHA (1 gg/ml), or cells only. Cells were cultured at 370C in a humidified atmosphere of 95% air, 5% CO2 for 72 h. I HLA typing. HLA typing was carried out as previously described (14) using the 11th Histocompatibility Workshop-validated antisera in a complement-mediated microcytotoxicity test.
Results
Proliferation ofPBL. The (Fig. 1). .=controls By contrast, peptide 257-269 induced significant proliferative responses only among MG patients, with no responses in controls (Fig. 1) . In six of the patients the SI was between 2.6 and 9.0, and four of these also gave moderate responses to purified Torpedo AChR (Fig. 2) . None of the controls gave an SI > 2.5 with this peptide as illustrated by the six examples in Fig. 2 .
The remaining positive responses were largely confined to the region 125-143. In native AChR, there is a disulphide bond (S-S) between cysteines 128 and 142, reproduced in peptide 125-143. Peptide 125-143 is identical except that it has a serine at 128, and therefore no S-S bond: this is also absent in the shorter peptide 129-143. A total of nine MG patients responded to the sequence 125-143 (Fig. 3) (Fig. 1) . 7 of the 17 controls also showed positive responses to peptide 129-143 and peptide 125-143 and 125-143 (S-S) (Fig. 1) . One of these was a healthy laboratory worker who also responded on the same occasion to purified Torpedo AChR, giving an SI of 4.0 to peptide 129-143. These results, expressed in counts per minute, from MG patients and controls are shown in Fig. 3 .
Proliferation of thymic and lymph node cells. Low-density cells from only two ofthe six hyperplastic MG thymus samples responded to peptide 125-143 (S-S) (SI = 2.7 and 4.1) whereas PBL from these two cases were unreactive, but did respond in one of the remaining four cases. Low-density cells from one thymoma showed an SI of 2.7 and 2.8 to peptide 125-143 (S-S) and 129-143, respectively, but both the adjacent uninvolved thymus and the PBL were unresponsive to this peptide.
The three lymph node cell samples gave SIs of 23.6, 8.2, and 2.4 with peptide 125-143 (S-S), whereas the values for PBL in the same cases were 10, 2.9, and 1.4, respectively.
There was no evidence of a response to peptide 257-269 from any of the thymus and lymph node samples. Blood lymphocytes from six of these seven patients had also failed to respond to this peptide, although PBL from a thymoma patient (MB) had shown a response (Fig. 2) . Proliferation oflymphocyte lines. Lymphocyte lines raised against purified Torpedo AChR had previously been established from three patients whose PBL had shown proliferative responses (SI > 2.5-8.3) at the first test. These lines have been maintained in culture for 3 mo to 1 yr and have consistently shown a positive response to Torpedo AChR although this varied quantitatively from week to week. Lines were also established from PBL of patients CB and HG using peptide 125-143 (S-S).
Lines raised against Torpedo AChR were tested against all the peptides at concentrations ranging from 50 to 0.001 tg/ml. There was no evidence of stimulation by any of the peptides for any of the three lines tested nor from a clone (C9) derived from one of them (Fig. 4) , even though responses to Torpedo AChR were high at the time of testing (SI = 6-10).
MYASTHENIC PATIENTS 6 5. HLA type and peptide responsiveness. The HLA types of the majority of the patients and of the controls who responded to peptides are shown in Table II . Although there is a high overall frequency of HLA-B8 and DR3, these may be slightly underrepresented in the responders, who show a small excess of DR2 (neither being statistically significant).
Discussion
The human AChR a-chain sequence contains 22 of the recurring amino acid motifs identified by Rothbard and Taylor (8) . The 11 peptides used here were selected because they include many ofthese sites (Table I) and closely resemble other known T cell determinants. These authors have already successfully identified T cell epitopes in influenza virus haemagglutinin, matrix and nucleoproteins (11, 15) and in ovalbumin (16) . This approach has now apparently located a further site in the human AChR (257-269) that is recognized by -20% of our MG cases and none of 17 controls. This peptide sequence is identical in Torpedo AChR, and indeed PBL responding to this peptide also responded to native Torpedo AChR in most cases. The responses to peptide 257-269 suggest that a previously unsuspected external region ofthe AChR (between two of the transmembrane domains) may be an important focus for autoreactive T cells in MG.
A second sequence (125-143), including one of the intrachain S-S bonds, also stimulates T cells in a similar proportion ofpatients, and had previously been suggested as an important T cell epitope in experimental MG (EAMG) in rats (2) either S-S linked or unlinked. Similarly, two patients (HG and FC) did not distinguish between the straight and S-S-looped variants of this peptide (Fig. 3) . However, other cases showed a ( 18) . The responses to peptide 125-143 in controls may imply a cross-reaction with some environmental antigen (e.g., bacterial) that could be coincidental or might be involved in provoking autoreactivity in susceptible subjects. Alternatively, T cell reactivity to AChR may conceivably be more widespread than previously suspected, and these clones may be controlled more effectively in healthy subjects than in myasthenics or indeed T cells reactive to this peptide may not inevitably be pathogenic in humans.
It is interesting that peptides 1-15, 84-98, and 99-116 stimulated so poorly since the majority of autoantibodies appear to bind near this area (1, 5 Some of the responders recognized Torpedo AChR in addition to peptides 129-143 and 257-269 (e.g., patient HG). Their AChR-reactive T cells are evidently heterogeneous, which implies that selective therapy with clonotypic antibodies to the T cell receptor may not always be straightforward.
There was no clear association detected between HLA type and the T cell epitopes recognized: if anything, there was a slight preference for DR2 rather than DR3, in spite of the very strong overall HLA-B8-DR3 bias in young-onset MG patients in the United Kingdom (Table II) (14) . It has been suggested that the latter is a nonspecific predisposition (23) and if the present tentative conclusions can be confirmed, they may support this view. However, in a similar study, Brocke and his colleagues (manuscript submitted for publication) have found responses to peptide 257-269 that were apparently related to the presence of HLA-B8 and DR3 in myasthenics (and some controls) in Israel. More frequently, they found reactivity to peptide 195-212 that was confined to DR5' subjects. The MG population in Israel is clearly different from ours: perhaps the rarity of the DR5 allele in our subjects (2 of 33 MG patients) (Table II) 
